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Abstract. 
Malaria remains a significant cause of morbidity and mortality in West Africa, but the contribution of other vector-
borne infections (VBIs) to the burden of disease has been understudied. We used rapid diagnostic tests (RDTs) for 
three VBIs to test blood samples from 1,795 febrile residents of Bo City, Sierra Leone, over a 1-year period in 
2012–2013. In total, 24% of the tests were positive for malaria, fewer than 5% were positive for markers of dengue 
virus infection, and 39% were positive for IgM directed against chikungunya virus (CHIKV) or a related alphavirus. 
In total, more than half (55%) of these febrile individuals tested positive for at least one of the three VBIs, which 
highlights the very high burden of vector-borne diseases in this population. The prevalence of positives on the 
Chikungunya IgM and dengue tests did not vary significantly with age (P > 0.36), but higher rates of malaria were 
observed in children < 15 years of age (P < 0.001). Positive results on the Chikungunya IgM RDTs were moderately 
correlated with rainfall (r2 = 0.599). Based on the high prevalence of positive results on the Chikungunya IgM RDTs 
from individuals Bo and its environs, there is a need to examine whether an ecological shift toward a greater burden 
from CHIKV or related alphaviruses is occurring in other parts of Sierra Leone or the West African region. 
Malaria and other vector-borne infections (VBIs) are responsible for nearly 10% of the 
disability-adjusted life years lost globally each year to infectious diseases,1 and they cause nearly 
1 million deaths worldwide annually.2 Sierra Leone, in West Africa, has one of the highest rates 
of malaria transmission among African countries,3 with about half of all outpatient clinic 
consultations and a sizeable proportion of inpatient hospitalizations due to malaria.4,5 However, 
many patients with febrile illnesses have unknown infections. For example, 27.3% of 
hospitalized febrile patients in Kenema, Sierra Leone, in 2011–2012 had malaria, but more than 
half (53.4%) of the patients did not have a known diagnosis at discharge.5 Little is known about 
the epidemiological burden from nonmalarial VBIs in Sierra Leone, but preliminary reports of 
circulation of other VBIs such as chikungunya virus (CHIKV) and dengue virus have been 
reported.6–9 
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As part of a larger study of the etiology of febrile illnesses in and around Bo, Sierra Leone, 
Mercy Hospital Research Laboratory personnel tested 1,795 blood samples from adults and 
children ages 6 and older who were residents of Bo city and presented to the laboratory with self-
reported or clinically confirmed fever with onset within the previous 7 days. Detailed 
symptomatic information beyond febrile status was obtained for about one in three participants 
(N = 565). Informed consent from patients (or, for minor children, consent from their parents) 
was obtained and documented before collection of the survey data and biological specimens. The 
research protocol was approved by the institutional review boards of Njala University, George 
Mason University, the Liverpool School of Tropical Medicine, the U.S. Naval Research 
Laboratory, and the Sierra Leone Ethics and Scientific Review Committee. 
Participants’ blood samples were tested with at least one of four commercial rapid diagnostic 
tests (RDTs) for VBIs according to manufacturer’s instructions: malaria was tested with 
Paracheck™ (Orchid Biomedical Systems, Goa, India) and Malaria Ag Pf/Pan (SD Bioline, 
Gyeonggi-do, Republic of Korea); chikungunya with Chikungunya IgM (SD Bioline); and 
dengue with Dengue Duo IgG/IgM/NS1 (SD Bioline). For 1,260 patients, the sample volume 
was sufficient to allow tests for all three VBIs to be performed. Although some of the tests 
measure multiple markers, a positive result for any of the markers was designated as a positive 
test. 
Malarial antigens were detected in 23% of the samples tested using one or both of the malaria 
RDTs (Table 1). There were no differences in malarial detection by gender (P = 0.898) but rates 
were higher in children than in adults (P < 0.001). There was no significant correlation between 
rainfall and the percentage of tests that were positive for malaria by month (r2 = 0.034; Table 
2).10 The malaria detection rates determined here are significantly lower than those documented 
elsewhere.3,8 This disparity may reflect an actual decrease in the malaria burden in Bo, or they 
could be due to the cohort tested, the age distribution of participants, or the generally poorer 
sensitivity of the RDTs as compared with gold standard microscopic tests, enzyme-linked 
immunosorbent assays (ELISAs), and polymerase chain reaction.11 However, the two malaria 
tests used here meet World Health Organization (WHO) procurement criteria for use in resource-
limited environments,12 and in spite of sensitivity issues, RDTs may improve management of 
malaria in settings with inadequate diagnostic facilities.13,14 
In total, 4.5% of the participants tested positive for at least one marker of dengue virus 
(DENV) infection. No significant difference was observed by gender (P = 0.311) or by age (P = 
0.368). The overwhelming majority of these participants (95%) were positive for the presence of 
anti-DENV IgG, but not anti-DENV IgM or NS1 antigen (Supplemental Table 1), suggesting 
that a high proportion of DENV-positive participants had antibodies from previous infections 
rather than suffering from an acute dengue infection at the time of testing. Although two-thirds 
of the DENV-positive samples were collected in June, the prevalence of DENV was not 
significantly correlated with rainfall (r2 = 0.042), but this may be due to the low number of 
positive samples. The low rates of DENV IgG/IgM seropositivity observed here agree with a 
recent study in neighboring Kenema,9 but several other papers report significantly higher 
seroprevalence of anti-DENV antibodies.7,8 
A high percentage (39%) of participants had positive results on the Chikungunya IgM RDT. 
Participants who tested positive were significantly more likely than those with negative results to 
report joint pain and/or backaches (P < 0.001), both characteristic symptoms of CHIKV 
infections (Supplemental Table 2). We observed no significant difference in results for the 
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Chikungunya IgM tests by gender (P = 0.934) or age (P = 0.391). Rates of positive test results 
showed a moderate correlation with monthly rainfall amounts (r2 = 0.599). The high proportion 
of positive test results on the Chikungunya IgM RDT agrees with our previous report from Bo6 
and with another study performed with samples collected in the same time (35%).8 A separate 
study using samples from 2006 to 2008 documented much lower seroprevalence.9 
The manufacturer of the Chikungunya IgM RDT reports a sensitivity of 97.1% and 
specificity of 91.1% compared with ELISAs.15 However, other studies have documented lower 
sensitivity and specificities,16–18 suggesting that at least some of the positive samples may be 
false positive or may be due to cross-reactivity with other uncharacterized or unidentified 
alphaviruses. Indeed, a recent study at the Kenema Government Hospital documented a 55.8% 
seroprevalence rate for pan-alphavirus antibodies, indicating widespread alphaviral exposure.19 
Although the test used here claims to target anti-CHIKV antibodies, we cannot rule out the 
possibility of cross-reaction with other related alphaviruses; to date, we have been unable to 
confirm the presence of CHIKV via molecular assays or culture. These results suggest that a 
significant proportion of population of Bo and its environs has been exposed to chikungunya or 
an as yet unidentified alphaviral species. It would be beneficial to retest residents of Bo using 
more definitive tests for CHIKV and related alphaviruses to more precisely identify the 
alphaviral agents causing so many febrile infections. 
Among the 1,260 participants tested for all three VBIs, approximately 11% had positive 
results on more than one test, suggesting possible coinfections (Figure 1). About 45% of 
participants did not test positive for any of the three VBIs, and the etiological agent of fever 
remains unknown. However, it is remarkable that half of the febrile individuals in our study 
tested positive for malaria or chikungunya (or a similar alphavirus), which suggests a heavy 
burden from vector-borne disease in this city. 
One of the limitations of this study is the poor overall sensitivity of RDT technology and 
single-timepoint testing of samples collected from febrile patients reporting to the clinic. 
Although WHO recognizes the role of RDTs in management of malaria in resource-limited 
settings,12,13 the sensitivity or selectivity of RDTs may limit their effectiveness in diagnostic 
applications. Nevertheless, the VBI tests used here can serve as valuable tools to identify 
potential public health issues. Furthermore, the concentrations of both antigens and antibodies 
are greatly affected by the time of testing, a better option would be to test each subject at 
multiple timepoints to distinguish acute and convalescent phases. While the Chikungunya IgM 
test likely missed many actual CHIKV infections or detected other alphaviral infections, the high 
numbers of positives observed here point to the possibility of a significant alphaviral problem in 
the tested population, which requires further investigation. A larger set of VBI tests for various 
alphaviruses (such as O’nyong-nyong virus), bunyaviruses (such as Tahyna virus), and 
flaviviruses (such as West Nile, Zika, and yellow fever viruses)20,21 should be used in Bo and its 
environs to identify the true burden of nonmalarial VBIs in this area. 
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FIGURE 1. Overlap in vector-borne infection (VBI) rapid diagnostic test results in 1,260 samples tested for all three 
VBIs. 
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TABLE 1 
Test results by gender and age, July 2012 to June 2013, Bo, Sierra Leone 
Infection Population No. of tested No. of positive % Positive P value 
All 1,576 361 22.9 – 
Male 611 141 23.1 
Female 965 220 22.8 0.898 
Age 6–14 88 39 44.3 
Age 15–29 444 105 23.6 
Age 30–44 271 56 20.7 
Malaria 
Age 45+ 400 74 18.5 
< 0.001 
All 1,392 62 4.5 – 
Male 534 20 3.7 
Female 858 42 4.9 0.311 
Age 6–14 8 0 0.0 
Age 15–29 376 21 5.6 
Age 30–44 238 19 8.0 
Dengue 
Age 45+ 326 16 4.9 
0.368 
All 1,668 645 38.7 – 
Male 648 249 38.4 
Female 1,020 394 38.6 0.934 
Age 6–14 93 29 31.2 
Age 15–29 490 192 39.2 
Age 30–44 283 102 36.0 
Chikungunya 
Age 45+ 427 149 34.9 
0.391 
TABLE 2 
Percentage of positive tests each month for malaria, dengue, and chikungunya 





















July 2012 73/148 37.1 0/148 0 73/148 49.3 46.9 
August 2012 28/134 20.9 0/135 0 80/135 59.3 53.7 
September 
2012 43/131 32.8 2/131 1.5 69/131 52.7 42.1 
October 2012 8/69 11.6 0/65 0 21/68 30.9 28.5 
November 
2012 29/104 27.9 0/104 0 23/66 34.8 8.6 
December 
2012 17/124 13.7 0/122 0 46/124 27.1 1.8 
January 2013 39/160 24.4 14/157 8.9 48/138 34.8 0.6 
February 2013 35/137 25.5 5/42 11.9 45/137 32.8 1.3 
March 2013 28/115 24.3 0/75 0 51/174 29.3 3.5 
April 2013 23/91 25.3 0/67 0 47/130 36.2 9.5 
May 2013 27/124 21.8 0/28 0 63/137 37.7 19.7 




– 0.034 – 0.042 – 0.599 1.00 
CHIKV = chikungunya virus; DENV = dengue virus. 
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SUPPLEMENTAL TABLE 1 
Positive results for individual markers of VBI using RDTs to test blood samples from febrile individuals, July 2012 




results Test Analyte % Positive 
Chikungunya IgM 1,700 655 38.5 
NS1 1,149 1 0.1 
IgM 1,421 2 0.1 Dengue 
IgG 1,421 60 4.2 
Paracheck™ Plasmodium falciparum (HRP2) 723 148 20.5 
P. falciparum (HRP2) 882 226 25.6 Malaria Pf/Pan Malaria Pan (pLDH) 882 113 12.8 
RDT =rapid diagnostic test; VBI = vector-borne infection. 
SUPPLEMENTAL TABLE 2 
Prevalence of symptoms other than fever for 565 participants for whom detailed symptomatic descriptions were 
recorded 
All febrile individuals m 
(N = 565) 
Individuals with positive 
malaria tests (N = 153) 
Individuals with positive 
CHIKV tests (N = 250) Symptom 
Headache 97/565 (17.3%) 35 (22.9%)* 52 (20.8%) 
Body aches 90 (15.9%) 23 (15.0%) 44 (17.6%) 
Cough 36 (6.4%) 6 (3.9%) 22 (8.8%) 
Abdominal discomfort and/or 
diarrhea 34 (6.0%) 14 (9.2%) 15 (6.0%) 
Backache 31 (4.6%) 11 (7.2%) 25 (10.0%)* 
Nausea and/or vomiting 25 (4.4%) 9 (5.9%) 11 (4.4%) 
Side pain 20 (3.5%) 4 (2.6%) 18 (7.2%)* 
Joint pain 15 (2.7%) 6 (3.9%) 13 (5.2%)* 
Dizziness 15 (2.7%) 5 (3.3%) 8 (3.2%) 
Chest pain 8 (1.4%) 3 (2.0%) 5 (2.0%) 
Neck pain 4 (0.7%) 2 (1.3%) 4 (1.6%) 
Hypertension 4 (0.7%) 1 (0.7%) 0 (0.0%) 
CHIKV = chikungunya virus; DENV = dengue virus. The number of DENV-positive individuals was too small to 
provide meaningful analysis. 
* Prevalence of symptom is significantly higher in participants with positive tests rather than negative tests (P < 
0.05, 2 test, corrected for continuity). 
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